Sustained delivery of GDNF: Towards a treatment for Parkinson's disease

Brain Research Reviews

Volumn 36, Issue 2-3, 2001, Pages 222-229

  Zurn, Anne D ^a   Widmer, Hans R ^b   Aebischer, Patrick ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Animal model; Cell encapsulation; Cell transplantation; Clinical trial; Gene therapy; Glial cell line derived neurotrophic factor; Neurotrophic factor; Parkinson's disease; Viral vectors

Indexed keywords

DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; RECOMBINANT PROTEIN; VIRUS VECTOR;

ANIMAL BEHAVIOR; CELL DEATH; CELL LINE; CELL LOSS; CELL SURVIVAL; CLINICAL TRIAL; DISEASE COURSE; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DRUG INDUCED DISEASE; GENE TARGETING; GENE THERAPY; GENETIC CODE; GENETIC ENGINEERING; HORMONE SUBSTITUTION; HUMAN; LENTIVIRINAE; MONKEY; NERVE CELL DIFFERENTIATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; RODENT; TISSUE GRAFT;

ANIMALS; BRAIN TISSUE TRANSPLANTATION; CELLS, CULTURED; DIFFUSION CHAMBERS, CULTURE; GENE THERAPY; GENETIC VECTORS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; PARKINSONIAN DISORDERS; SUBSTANTIA NIGRA;

EID: 0034750770     PISSN: 01650173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0173(01)00098-4     Document Type: Review

References (60)

1. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis
2. The GDNF family ligands and receptors - Implications for neural development
3. Adenovirus in the brain: Recent advances of gene therapy for neurodegenerative diseases
4. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain
5. Lentiviral vectors as a gene delivery system in the mouse midbrain: Cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF
6. Towards a neuroprotective gene therapy for Parkinson's disease: Use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model
7. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector
8. Ethical guidelines for the use of human embryonic or fetal tissue for experimental and clinical neurotransplantation and research
9. Improving the survival of grafted dopaminergic neurons: A review of current approaches
10. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease
11. Ontogeny and distribution of glial cell line-derived neurotrophic factor (GDNF) mRNA in rat
12. Dopaminergic neurons protected from degeneration by GDNF gene therapy
13. Gene therapy in the CNS
14. Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease
15. Prospects for new restorative and neuroprotective treatments in Parkinson's disease
16. Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease
17. Transplantation of embryonic dopamine neurons for severe Parkinson's disease
18. Effects of glial cell line-derived neurotrophic factor on the nigrostriatal dopamine system in rodents and non-human primates
19. Neuroprotective and neurorestorative properties of GDNF
20. Functional recovery in parkinsonian monkeys treated with GDNF
21. Glial cell line-derived neurotrophic factor (GDNF): A drug candidate for the treatment of Parkinson's disease
22. GDNF: A potent survival factor for motoneurons present in peripheral nerve and muscle
23. Oxidative mechanisms in nigral cell death in Parkinson's disease
24. GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF
25. Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics
26. Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor
27. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: Intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system
28. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
29. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease
30. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease
31. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease
32. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease
33. Parkinson's disease. First of two parts
34. Parkinson's disease. Second of two parts
35. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease
36. GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons
37. Update on fetal transplantation: The Swedish experience
38. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease
39. Encapsulated cells as therapy
40. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats
41. Glial cell line-derived neurotrophic factor: The lateral cerebral ventricle as a site of administration for stimulation of the substantia nigra dopamine system in rats
42. Lentiviruses as gene transfer agents for delivery to non-dividing cells
43. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient
44. Neuronal GDNF expression in the adult rat nervous system identified by in situ hybridization
45. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease
46. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle
47. Glial cell line-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafts
48. The GDNF protein family: Gene ablation studies reveal what they really do and how
49. GDNF slows loss of motoneurons but not axonal degeneration or premature death of pmn/pmn mice
50. Implants of polymer-encapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor improve survival, growth, and function of fetal dopaminergic grafts
51. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
52. Growth/differentiation factor 5 and glial cell line-derived neurotrophic factor enhance survival and function of dopaminergic grafts in a rat model of Parkinson's disease
53. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo
54. Lentiviral vectors: Turning a deadly foe into a therapeutic agent
55. Complementary and overlapping expression of glial cell line-derived neurotrophic factor (GDNF), c-ret proto-oncogene, and GDNF receptor-alpha indicates multiple mechanisms of trophic actions in the adult rat CNS
56. Peripheral expression and biological activities of GDNF, a new neurotrophic factor for avian and mammalian peripheral neurons
57. GDNF reduces drug-induced rotational behavior after medial forebrain bundle transection by a mechanism not involving striatal dopamine
58. In vivo neurotrophic effects of GDNF on neonatal and adult facial motor neurons
59. Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys
60. Glial cell line-derived neurotrophic factor (GDNF), a new neurotrophic factor for motoneurones